Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.

"Declarations Ethics approval and consent to participateApproval for this study was obtained from the National Medical Ethics Committee of the Republic of Slovenia (reference number: KME 0120–357/2018/8). All patients signed a written informed consent prior to inclusion in the study. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This study was funded by Research Program P3-0308 of the Slovenian Research Agency, University Medical Centre Ljubljana (Funding number: 20210022), Amgen and Sanofi. The funding source did not have any role in study design, nor in the collection, analysis, and interpretation of the data, nor in the writing of the report, and in the decision to submit the article for publication."

"Trial registration The protocol for this study was registered with clinicaltrials.gov on November, 3 2020 under registration number NCT04613167."